Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

UniCardioMab Universal Cardiac Mesoangioblasts for treating DMD Dilated Cardiomyopathy

Coordinator
Ospedale San Raffaele SRL, Italy
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213566

What the project is doing

In the project's own words, from its summary on CORDIS.

Dilated cardiomyopathy (DCM) is the second most common cause of heart failure, currently treated with drugs that delay progress towards heart transplantation. There are currently many attempts to treat DC with stem cells or their extracellular vesicles or AAV vectors: none reached efficacy so far. The applicant has a long track record in cell and gene therapy for muscular dystrophy. He pioneered systemic intra-arterial transplantation of mesoangioblasts (blood vessel-derived progenitors) and, thanks to a previous ERC grant, succeeded in creating immortal, universal donor mesoangioblasts.

Edited cells do not activate an immune response in vitro or in vivo. Muscular dystrophy also affects the heart causing a DCM, but a simple extension of this strategy is problematic since the existence of resident cardiac stem cells is controversial and cardiac mesoangioblasts do not spontaneously differ-entiate into cardiomyocytes. iPS cell-derived cardiac progenitors are promising but until now for lo-calised lesions such as myocardial infarcts.

To address this problem we will produce immortal, im-mune privileged cardiac mesoangioblasts and will convert them to cardioblasts, in vitro expression of cardiac transcription factors. Since conversion takes about two weeks, we will test different settings to allow cells so that they would home and differentiate in vivo in the areas of damage, characterized by inflammation. The applicant is in the unique position to test feasibility of this project for future translation into a novel clinical protocol.

Topics

Who is involved

OrganisationCityCountryRole
Ospedale San Raffaele SRLMilanoItalyCoordinator
Day One Societa a Responsabilita LimitataRoma RmItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI